| RHYTHM PHARMACEUTICALS |
| USA |
| Gesundheit |
| US76243J1051 / A2H5A0 |
| 1RV (Frankfurt) / RYTM (NASDAQ) |
| FRA:1RV, ETR:1RV, 1RV:GR, NASDAQ:RYTM |
| - |
| https://www.rhythmtx.com/ |
|
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, particularly those involving hyperphagia and severe obesity. Its lead product, IMCIVREE ..
>Volltext.. |
| 5240.76 Mio. EUR |
| 5142.36 Mio. EUR |
| 187.74 Mio. EUR |
| -169.58 Mio. EUR |
| -175.21 Mio. EUR |
| -2.71 EUR |
| 196.25 Mio. EUR |
| 53.72 Mio. EUR |
| -103.31 Mio. EUR |
| 3.3 |
| 48.58% |
| -12.5% |
| - |
| - |
| - |
| RHYTHM PHARMACEUTICALS, RHYTHM PHARMA, RHYTHM PHARMACEUTICAL |
| 15.06.26 |
|